Pacira BioSciences, Inc. (PCRX) Cash Flow Statement

The gap between net income and operating cash flow is substantial, driven by non-cash charges like D&A and SBC, which totaled $36.3M in Q2 2026 versus net income of $4.7M. This suggests earnings quality is high on a cash basis, but investors should note that SBC alone exceeds net income, implying that reported profitability understates the true cash-generative capacity of the business. The consistent OCF/NI ratios above 2x across most quarters indicate that accruals are not inflating earnings, but the reliance on non-cash add-backs warrants monitoring for sustainability.

FCF has been consistently positive, ranging from $9.3M in Q2 2025 to $57.0M in Q3 2025, with the most recent quarter at $56.1M. This stability contrasts with the volatile net income, which swung to a loss in Q2 2025 and Q3 2024, indicating that cash flow is a more reliable indicator of operational health. The FCF margin of 29.2% in Q2 2026 is well above the peer average, suggesting PCRX is efficiently converting revenue into cash, though the low capex intensity (0.7% of revenue) implies that growth investments are minimal, which may limit future expansion.

Capex has been consistently small, ranging from $0.2M to $8.5M per quarter, which is typical for a specialty pharma with outsourced manufacturing. This low capex suggests that the company is not investing heavily in new capacity, which may be appropriate given the mature EXPAREL franchise, but it also raises questions about whether the company is underinvesting in future growth drivers. The depreciation and amortization of roughly $21M per quarter is significantly higher than capex, implying that the asset base is being run down, which could eventually require catch-up investment.

The large negative working capital change in Q2 2025 indicates a significant cash outflow, likely due to inventory build-up or slower collections, while the positive changes in other quarters suggest efficient collection. This volatility may be tied to channel loading or seasonal demand patterns, as surgical volumes peak in Q4. Investors should monitor the working capital cycle closely, as swings can distort quarterly cash flow comparisons and may signal underlying demand shifts.

Buybacks have been a consistent use of cash, with $50M in Q1 2026, $48.2M in Q4 2025, and $50M in Q3 2025, totaling $223.2M over the period. This aggressive repurchase activity suggests management believes the stock is undervalued, but it also consumes cash that could be used for R&D or acquisitions. Given the thin net margin and the need to defend EXPAREL's patent position, the sustainability of this buyback pace is questionable, especially if cash flow deteriorates.

The cumulative gap of over $500M between operating cash flow and net income is primarily due to non-cash items like D&A, SBC, and impairment charges, which totaled $143.5M in Q3 2024 alone. This divergence indicates that reported earnings significantly understate the company's cash-generative ability, but it also raises concerns about the quality of earnings, as the persistent losses may reflect underlying operational challenges. Investors should focus on cash flow as the more reliable indicator of financial health, but the reliance on non-cash add-backs warrants scrutiny.